Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

Tamargo, J; Kjeldsen, K P; Delpón, E; Semb, A G; Cerbai, E; Dobrev, D; Savarese, G; Sulzgruber, P; Rosano, G; Borghi, C; Wassman, S; Torp-Pedersen, C T; Agewall, S; Drexel, H; Baumgartner, I; Lewis, B S; Ceconi, C; Kaski, J C; Niessner, A (2022). Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European heart journal. Cardiovascular pharmacotherapy, 8(4), pp. 406-419. Oxford University Press 10.1093/ehjcvp/pvac005

Text TamargoJ_FacingTheChallengeOfPolypharmacyOlderPeaopleCardiovascDisease_EurHeartJCardiovascPharmacother_2022.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Author holds Copyright Download (1MB) | Request a copy

Population ageing has resulted in an increasing number of older people living with chronic diseases (multimorbidity) requiring five or more medications daily (polypharmacy). Ageing produces important changes in the cardiovascular system and represents the most potent single cardiovascular risk factor. Cardiovascular diseases (CVD) constitute the greatest burden for older people, their caregivers, and healthcare systems. Cardiovascular pharmacotherapy in older people is complex because age-related changes in body composition, organ function, homeostatic mechanisms and comorbidities modify the pharmacokinetic and pharmacodynamic properties of many commonly used cardiovascular and non-cardiovascular drugs. Additionally, polypharmacy increases the risk of adverse drug reactions and drug-interactions, which in turn can lead to increased morbi-mortality and healthcare costs. Unfortunately, evidence of drug efficacy and safety in older people with multimorbidity and polypharmacy is limited because these individuals are frequently under-represented/excluded from clinical trials. Moreover, clinical guidelines are largely written with a single-disease focus and only occasionally address the issue of coordination of care, when and how to discontinue treatments, if required, or how to prioritize recommendations for patients with multimorbidity and polypharmacy. This review analyses the main challenges confronting healthcare professionals when prescribing in older people with CVD, multimorbidity and polypharmacy. Our goal is to provide information that can contribute to improve drug prescribing, efficacy, and safety, as well as drug adherence and clinical outcomes.

Interest & Impact

Downloads

1 since deposited on 17 Mar 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item